CASI Pharmaceuticals Inc. (CASI)
CASI Pharmaceuticals Statistics
Share Statistics
CASI Pharmaceuticals has 13.4M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 13.4M |
Shares Change (YoY) | 0% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 11.14% |
Shares Floating | 4.77M |
Failed to Deliver (FTD) Shares | 243 |
FTD / Avg. Volume | 1.59% |
Short Selling Information
The latest short interest is 75.57K, so 0.56% of the outstanding shares have been sold short.
Short Interest | 75.57K |
Short % of Shares Out | 0.56% |
Short % of Float | 1.97% |
Short Ratio (days to cover) | 2.36 |
Valuation Ratios
The PE ratio is -3.55 and the forward PE ratio is -1.16. CASI Pharmaceuticals's PEG ratio is 0.12.
PE Ratio | -3.55 |
Forward PE | -1.16 |
PS Ratio | 2.82 |
Forward PS | 0.3 |
PB Ratio | 3.96 |
P/FCF Ratio | -4.31 |
PEG Ratio | 0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CASI Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.55, with a Debt / Equity ratio of 0.88.
Current Ratio | 3.55 |
Quick Ratio | 2.6 |
Debt / Equity | 0.88 |
Debt / EBITDA | -0.99 |
Debt / FCF | -0.96 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $192.49K |
Profits Per Employee | $-153.06K |
Employee Count | 176 |
Asset Turnover | 0.45 |
Inventory Turnover | 0.87 |
Taxes
Income Tax | -81K |
Effective Tax Rate | 0.31% |
Stock Price Statistics
The stock price has increased by -32.11% in the last 52 weeks. The beta is 0.61, so CASI Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.61 |
52-Week Price Change | -32.11% |
50-Day Moving Average | 2.36 |
200-Day Moving Average | 4.53 |
Relative Strength Index (RSI) | 42.87 |
Average Volume (20 Days) | 15.25K |
Income Statement
In the last 12 months, CASI Pharmaceuticals had revenue of 33.88M and earned -26.94M in profits. Earnings per share was -2.02.
Revenue | 33.88M |
Gross Profit | 20.05M |
Operating Income | -25.08M |
Net Income | -26.94M |
EBITDA | -21.54M |
EBIT | -25.28M |
Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has 17.08M in cash and 21.24M in debt, giving a net cash position of -4.16M.
Cash & Cash Equivalents | 17.08M |
Total Debt | 21.24M |
Net Cash | -4.16M |
Retained Earnings | -660.82M |
Total Assets | 63.62M |
Working Capital | 32.41M |
Cash Flow
In the last 12 months, operating cash flow was -19.97M and capital expenditures -2.24M, giving a free cash flow of -22.21M.
Operating Cash Flow | -19.97M |
Capital Expenditures | -2.24M |
Free Cash Flow | -22.21M |
FCF Per Share | -1.66 |
Margins
Gross margin is 59.19%, with operating and profit margins of -74.03% and -79.51%.
Gross Margin | 59.19% |
Operating Margin | -74.03% |
Pretax Margin | -77.61% |
Profit Margin | -79.51% |
EBITDA Margin | -63.58% |
EBIT Margin | -74.03% |
FCF Margin | -65.55% |
Dividends & Yields
CASI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CASI is $6, which is 170.3% higher than the current price. The consensus rating is "Buy".
Price Target | $6 |
Price Target Difference | 170.3% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 2, 2022. It was a backward split with a ratio of 1:10.
Last Split Date | Jun 2, 2022 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -15.36 |
Piotroski F-Score | 1 |